FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246508578> ?p ?o ?g. }

• W4246508578 endingPage "A63" @default.
• W4246508578 startingPage "A62.2" @default.
• W4246508578 abstract "<h3>Background and objectives</h3> Baricitinib, an oral inhibitor of JAK1 and JAK2 signalling, improved signs and symptoms in patients with active rheumatoid arthritis (RA) who were methotrexate inadequate responders (MTX-IR) in a double-blind, placebo (PBO) controlled study. We investigated how a quantitative, multibiomarker disease activity score (MBDA) and its components are affected by treatment with baricitinib 4mg (n = 50) once daily compared to PBO (n = 79) during 12 weeks’ treatment in moderate-to-severe RA patients. <h3>Materials and methods</h3> Serum samples were collected at baseline and Weeks 4 and 12. MBDA scores and changes in individual MBDA components were subjected to post-hoc statistical analyses. <h3>Results</h3> At baseline, the proportion of patients with low, moderate, and high MBDA scores were similar in the 2 groups, as were median MBDA scores (PBO=44 vs. baricitinib=47). Unlike PBO-treated patients, baricitinib patients had decreased MBDA scores at 4 and 12 weeks compared to baseline (baricitinib=35.5 and 37.0 (p < 0.001) vs. PBO=46.0 and 45.0, respectively). Baricitinib-treated patients had significant (p < 0.05) median % decreases in MBDA components vs. PBO including C-Reactive Protein (-66.9 vs. 6.6/-56.1 vs. 8.2 at 4/12 weeks), Matrix metalloproteinase (MMP)-3 (-12.3 vs. 4.5/-14.5 vs. 6.3 at 4/12 weeks), serum amyloid A (-56.4 vs. 9.9/-37.6 vs. 9.2 at 4/12 weeks), soluble TNF receptor (-12.1 vs. -0.1/-12.0 vs. 1.2 at 4/12 weeks), VCAM-1 (-15.9 vs. 1.4/-12.1 vs. 1.0 at 4/12 weeks), and human cartilage glycoprotein 39; -26.2 vs. -0.5/-9.9 vs. -1.6 at 4/12 weeks). Compared to PBO, there were no significant changes for baricitinib-treated patients at either timepoint for epidermal growth factor (EGF), MMP-1, or vascular endothelial growth factor-A. For baricitinib-treated patients versus PBO, at 4 but not 12 weeks, Interleukin-6 and resistin were significantly decreased and at 12 but not 4 weeks, leptin was significantly increased. <h3>Conclusions</h3> Consistent with other indices of disease activity, the treatment of MTX-IR patients with baricitinib 4mg once daily resulted in a reduction in MBDA scores, by 4 weeks. Decreases in MBDA scores and the components were present at both 4 and 12 weeks. Reduction in the levels of inflammatory markers beyond those associated with an acute phase response is apparent in these patients." @default.
• W4246508578 created "2022-05-12" @default.
• W4246508578 creator A5017598610 @default.
• W4246508578 creator A5025408956 @default.
• W4246508578 creator A5026769070 @default.
• W4246508578 creator A5044638885 @default.
• W4246508578 creator A5047117557 @default.
• W4246508578 creator A5055441251 @default.
• W4246508578 creator A5065173509 @default.
• W4246508578 creator A5073987524 @default.
• W4246508578 creator A5080646462 @default.
• W4246508578 date "2016-02-01" @default.
• W4246508578 modified "2023-09-27" @default.
• W4246508578 title "A7.17 Effects of baricitinib on multibiomarker disease activity scores and their components in a phase 2b study in moderate-to-severe rheumatoid arthritis patients" @default.
• W4246508578 doi "https://doi.org/10.1136/annrheumdis-2016-209124.148" @default.
• W4246508578 hasPublicationYear "2016" @default.
• W4246508578 type Work @default.
• W4246508578 citedByCount "0" @default.
• W4246508578 crossrefType "journal-article" @default.
• W4246508578 hasAuthorship W4246508578A5017598610 @default.
• W4246508578 hasAuthorship W4246508578A5025408956 @default.
• W4246508578 hasAuthorship W4246508578A5026769070 @default.
• W4246508578 hasAuthorship W4246508578A5044638885 @default.
• W4246508578 hasAuthorship W4246508578A5047117557 @default.
• W4246508578 hasAuthorship W4246508578A5055441251 @default.
• W4246508578 hasAuthorship W4246508578A5065173509 @default.
• W4246508578 hasAuthorship W4246508578A5073987524 @default.
• W4246508578 hasAuthorship W4246508578A5080646462 @default.
• W4246508578 hasConcept C126322002 @default.
• W4246508578 hasConcept C142724271 @default.
• W4246508578 hasConcept C204787440 @default.
• W4246508578 hasConcept C27081682 @default.
• W4246508578 hasConcept C2777575956 @default.
• W4246508578 hasConcept C2781059491 @default.
• W4246508578 hasConcept C71924100 @default.
• W4246508578 hasConcept C90924648 @default.
• W4246508578 hasConceptScore W4246508578C126322002 @default.
• W4246508578 hasConceptScore W4246508578C142724271 @default.
• W4246508578 hasConceptScore W4246508578C204787440 @default.
• W4246508578 hasConceptScore W4246508578C27081682 @default.
• W4246508578 hasConceptScore W4246508578C2777575956 @default.
• W4246508578 hasConceptScore W4246508578C2781059491 @default.
• W4246508578 hasConceptScore W4246508578C71924100 @default.
• W4246508578 hasConceptScore W4246508578C90924648 @default.
• W4246508578 hasIssue "Suppl 1" @default.
• W4246508578 hasLocation W42465085781 @default.
• W4246508578 hasOpenAccess W4246508578 @default.
• W4246508578 hasPrimaryLocation W42465085781 @default.
• W4246508578 hasRelatedWork W1977601919 @default.
• W4246508578 hasRelatedWork W2071054988 @default.
• W4246508578 hasRelatedWork W2096960896 @default.
• W4246508578 hasRelatedWork W2158058290 @default.
• W4246508578 hasRelatedWork W2401514108 @default.
• W4246508578 hasRelatedWork W2414220780 @default.
• W4246508578 hasRelatedWork W2775812515 @default.
• W4246508578 hasRelatedWork W2783466784 @default.
• W4246508578 hasRelatedWork W2950575436 @default.
• W4246508578 hasRelatedWork W70445611 @default.
• W4246508578 hasVolume "75" @default.
• W4246508578 isParatext "false" @default.
• W4246508578 isRetracted "false" @default.
• W4246508578 workType "article" @default.